In a report released today, Matthew O’Brien from Piper Jaffray maintained a Buy rating on Align Tech (NASDAQ: ALGN), with a price target of $325. The company’s shares opened today at $310.13, close to its 52-week high of $315.79.
According to TipRanks.com, O’Brien is a top 100 analyst with an average return of 26.8% and a 70.5% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Apollo Endosurgery Inc, and Merit Medical Systems.
Currently, the analyst consensus on Align Tech is Strong Buy and the average price target is $320.63, representing a 3.4% upside.
In a report issued on May 21, Barclays also maintained a Buy rating on the stock with a $325 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $315.79 and a one-year low of $138.71. Currently, Align Tech has an average volume of 939.6K.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Raymond Larkin, a Director at ALGN sold 15,000 shares for a total of $3,966,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Align Technology, Inc. engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion.
